- The FDA approved Fennec Pharmaceuticals Inc's (NASDAQ: FENC) Pedmark to reduce the risk of chemo-induced ototoxicity in pediatric patients.
- Pedmark is indicated for pediatric patients one month of age, and older who have localized, non-metastatic solid tumors and have been treated with cisplatin infusions.
- This approval makes Pedmark the first and only treatment approved by the FDA in this area of significant unmet medical need.
- The approval comes after receiving two FDA complete response letters, one in August 2020 and another in November 2021.
- Pedmark is a formulation of sodium thiosulfate.
- The latest rejection came as the FDA has indicated that deficiencies have been identified following a recent inspection of the drug product manufacturer's manufacturing facility.
- In its Q2 earnings report, the company said it has built out the commercial organization over the past months with key hires in sales, market access, and field-based medical teams.
- Price Action: FENC shares are up 9.44% at $8.35 on the last check Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga